P/E ratio for Takeda Pharmaceutical (TAK)

P/E ratio history for Takeda Pharmaceutical from 2009 to 2026

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	29.9	-7.04%	🇺🇸 USA
Novartis NVS	21.6	-32.84%	🇨🇭 Switzerland
Pfizer PFE	37.2	15.56%	🇺🇸 USA
Amgen AMGN	25.7	-20.05%	🇺🇸 USA
Sanofi SNY	21.1	-34.36%	🇫🇷 France
Merck MRK	116	259.85%	🇺🇸 USA
GSK plc GSK	14.6	-54.60%	🇬🇧 UK
Seagen SGEN	-57.0	-277.43%	🇺🇸 USA
Dr. Reddy's Laboratories RDY	28.4	-11.78%	🇮🇳 India

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.